1
|
Natanov R, Wiesner O, Haverich A, Kühn C. Mechanical circulatory support in coronavirus disease-2019-positive patients with severe respiratory failure. Interact Cardiovasc Thorac Surg 2021; 33:489-493. [PMID: 33822952 PMCID: PMC8083392 DOI: 10.1093/icvts/ivab087] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 01/18/2021] [Accepted: 02/05/2021] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES Treatment of severe acute respiratory distress syndrome (ARDS) induced by severe acute respiratory syndrome coronavirus 2 has been heavily debated. Our goal was to describe our findings in patients with severe ARDS due to severe coronavirus disease 2019 (sCOVID-19) treated with venovenous extracorporeal membrane oxygenation (vv-ECMO). METHODS We retrospectively examined all patients treated with vv-ECMO for severe ARDS due to acute respiratory syndrome coronavirus 2. RESULTS In total, 13 patients were treated with vv-ECMO in our medical centre. The mean patient age was 48.1 years. Most patients were obese (69%) and male (85%). All patients were mechanically ventilated before ECMO. The mean time from intubation to proning was 16.6 h; the time from start of prone therapy to vv-ECMO implantation was 155.1 h. The mean total ECMO run time was 358 h. Significant reduction of positive end-expiratory pressure (P = 0.02), peak pressure (P = 0.001) and minute volume (P = 0.03) could be achieved after implantation of vv-ECMO. All patients showed an inflammatory response. Overall mortality was 30.7%: 1 patient died of mesenteric ischaemia; 3 patients died of multiple organ failure. A worse prognosis was seen in patients with highly elevated concentrations of interleukin-6. CONCLUSIONS The use of vv-ECMO in patients with sCOVID-19-induced ARDS is safe and associated with improved respiratory ventilation settings. The rate of immune system involvement plays a pivotal role in the development and outcome of sCOVID-19.
Collapse
Affiliation(s)
- Ruslan Natanov
- Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
| | - Olaf Wiesner
- Department of Pneumology, Hannover Medical School, Hannover, Germany
| | - Axel Haverich
- Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
| | - Christian Kühn
- Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
| |
Collapse
|
2
|
Flores-Oria CA, Saturno E, Ramanathan S, Martinez Castillo DJ, Kumar R, Ferrer N, Mossaad A, Tellez ME, Jon C, Waters SC, Mosquera RA. Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review. SAGE Open Med Case Rep 2021; 9:2050313X211029699. [PMID: 34262773 PMCID: PMC8252403 DOI: 10.1177/2050313x211029699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 06/14/2021] [Indexed: 11/22/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.
Collapse
Affiliation(s)
- Carlos A Flores-Oria
- Division of Pulmonology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | | | - Supriya Ramanathan
- Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Diana J Martinez Castillo
- Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | | | | | - Afnan Mossaad
- Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Maria E Tellez
- School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Cindy Jon
- Division of Pulmonology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Sara C Waters
- Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Ricardo A Mosquera
- Division of Pulmonology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| |
Collapse
|
3
|
Suzuki Y, Tanino Y, Nikaido T, Minemura H, Umeda T, Rikimaru M, Onuma T, Naito S, Takiguchi Y, Tomita H, Kawamata T, Togawa R, Sato Y, Uematsu M, Morimoto J, Kitakawa K, Tsukada Y, Nakamura K, Kanemitsu K, Iseki K, Shibata Y. Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin. Intern Med 2021; 60:457-461. [PMID: 33328409 PMCID: PMC7925270 DOI: 10.2169/internalmedicine.6326-20] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 11/01/2020] [Indexed: 12/13/2022] Open
Abstract
We herein report a case of severe coronavirus disease 2019 (COVID-19) in which high-dose intravenous immunoglobulin (IVIg) treatment achieved significant clinical improvement of deterioration of pulmonary inflammation after temporary clinical improvement. In the present case, clinical and radiological deterioration occurred despite a decrease in viral load, suggesting that deterioration was caused by reactivation of proinflammatory factors, such as tumor necrosis factor-α and interleukin-6, rather than direct viral effects. IVIg treatment may provide not only immunosuppressive effects but also inhibition of proinflammatory cytokines, indicating that treatment including IVIg may be effective by inhibiting cytokine storm in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection.
Collapse
Affiliation(s)
- Yasuhito Suzuki
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Yoshinori Tanino
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Takefumi Nikaido
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Hiroyuki Minemura
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Takashi Umeda
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Mami Rikimaru
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Takumi Onuma
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Shotaro Naito
- Department of General Internal Medicine, Fukushima Medical University, Japan
| | - Yoshinori Takiguchi
- Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Japan
| | - Hikaru Tomita
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Takaya Kawamata
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Ryuichi Togawa
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Yuki Sato
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Manabu Uematsu
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Julia Morimoto
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| | | | - Yasuhiko Tsukada
- Department of Emergency and Critical Care Medicine, Fukushima Medical University, Japan
| | - Kiwamu Nakamura
- Department of Infection Control, Fukushima Medical University, Japan
| | - Keiji Kanemitsu
- Department of Infection Control, Fukushima Medical University, Japan
| | - Ken Iseki
- Department of Emergency and Critical Care Medicine, Fukushima Medical University, Japan
| | - Yoko Shibata
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Japan
| |
Collapse
|
4
|
Jozwiak M, Chiche JD, Charpentier J, Ait Hamou Z, Jaubert P, Benghanem S, Dupland P, Gavaud A, Péne F, Cariou A, Mira JP, Nguyen LS. Use of Venovenous Extracorporeal Membrane Oxygenation in Critically-Ill Patients With COVID-19. Front Med (Lausanne) 2020; 7:614569. [PMID: 33363190 PMCID: PMC7758460 DOI: 10.3389/fmed.2020.614569] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 11/19/2020] [Indexed: 01/08/2023] Open
Abstract
Acute respiratory distress syndrome (ARDS) related to Coronavirus disease (COVID-19) is associated with high mortality. It has been suggested that venovenous extracorporeal membrane oxygenation (ECMO) was suitable in this indication, albeit the effects of ECMO on the mechanical respiratory parameters have been scarcely described. In this case-series, we prospectively described the use of venovenous ECMO and its effects on mechanical respiratory parameters in eleven COVID-19 patients with severe ARDS. Implantation of ECMO occurred 6 [3–11] days after the onset of mechanical ventilation. At the time of ECMO implantation, all patients received neuromuscular blocking agents, three (27%) received inhaled nitric oxide and prone positioning was performed in all patients with 4 [3−5] sessions of PP per patient. Under ECMO, the tidal volume was significantly decreased from 6.1 [4.0–6.3] to 3.4 [2.5–3.6] mL/kg of predicted body weight and the positive end-expiratory pressure level was increased by 25 ± 27% whereas the driving pressure and the mechanical power decreased by 33 ± 25% and 71 ± 27%, respectively. The PaO2/FiO2 ratio significantly increased from 68 [58–89] to 168 [137–218] and the oxygenation index significantly decreased from 28 [26–35] to 13 [10–15]. The duration of ECMO was 12 [8–25] days. Nine (82%) patients experienced ECMO-related complications and the main complication was major bleeding requiring blood transfusions. Intensive care unit mortality rate was 55% but no patient died from ECMO-related complications. In COVID-19 patients with severe ARDS, venovenous ECMO allowed ultra-protective ventilation, improved oxygenation and should be considered in highly selected patients with the most severe ARDS.
Collapse
Affiliation(s)
- Mathieu Jozwiak
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Jean-Daniel Chiche
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Julien Charpentier
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France
| | - Zakaria Ait Hamou
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Paul Jaubert
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France
| | - Sarah Benghanem
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Pierre Dupland
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Ariane Gavaud
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Frédéric Péne
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Alain Cariou
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Jean-Paul Mira
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,Université de Paris, Paris, France
| | - Lee S Nguyen
- Assistance Publique - Hôpitaux de Paris, Hôpitaux universitaires Paris-Centre, Hôpital Cochin, Service de Médecine Intensive Réanimation, Paris, France.,CMC Ambroise Paré, Research and Innovation, Neuilly-sur-Seine, France
| |
Collapse
|
5
|
Menzella F, Matucci A, Vultaggio A, Barbieri C, Biava M, Scelfo C, Fontana M, Facciolongo NC. COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidiscip Respir Med 2020; 15:708. [PMID: 33282284 PMCID: PMC7662457 DOI: 10.4081/mrm.2020.708] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 10/19/2020] [Indexed: 12/15/2022] Open
Abstract
The novel coronavirus called "Severe Acute Respiratory Syndrome Coronavirus 2" (SARS-CoV-2) caused an outbreak in December 2019, starting from the Chinese city of Wuhan, in the Hubei province, and rapidly spreading to the rest of the world. Consequently, the World Health Organization (WHO) declared that the coronavirus disease of 2019 (COVID-19) can be characterized as a pandemic. During COVID-19 several immunological alterations have been observed: in plasma of severe patients, inflammatory cytokines are at a much higher concentration ("cytokine storm"). These aspects are associated with pulmonary inflammation and parenchymal infiltrates with an extensive lung tissue damage in COVID-19 patients. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials (RCTs) for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments are currently being evaluated worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. As for ventilatory strategies, at the moment there are still no consistent data published about the different approaches and how they may influence disease progression. What will probably represent the real solution to this pandemic is the identification of a safe and effective vaccine, for which enormous efforts and investments are being put in place. This review will summarize the state-of-the-art of COVID-19 current treatment options and those potentially available in the future, as well as high flow oxygen therapy and non-invasive mechanical ventilation approaches.
Collapse
Affiliation(s)
- Francesco Menzella
- Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia
| | - Andrea Matucci
- Immunoallergology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence
| | | | - Chiara Barbieri
- Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia
| | | | - Chiara Scelfo
- Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia
| | - Matteo Fontana
- Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia
| | - Nicola Cosimo Facciolongo
- Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia
| |
Collapse
|